MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027 - TradingView
Кратко: MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027
Leadership is focused on advancing canvuparatide to full phase III enrollment and preparing for commercialization, while MBX 4291 targets once-monthly obesity treatment with key data expected in Q4. The platform supports a robust pipeline, with two new obesity candidates aiming for INDs by 2027.
🧭 Извлечение: ok
· confidence 90%
· диагностика
High confidence: full text extraction produced 402 characters.
High confidence: full text extraction produced 402 characters.
MBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027
Leadership is focused on advancing canvuparatide to full phase III enrollment and preparing for commercialization, while MBX 4291 targets once-monthly obesity treatment with key data expected in Q4. The platform supports a robust pipeline, with two new obesity candidates aiming for INDs by 2027.